全部 标题 作者 关键词 摘要
DOI: 10.3971/j.issn.1000-8578.2016.04.009
Keywords: One Case Report,Progress of Polyamidoamine Dendrimer Targeted System in Diagnosis and Treatment of Ovarian Cancer,Progress of Relationship between Matrix Metalloproteinases and Occurrence and Development of Ovarian Cancer,Platinum Resistance after Neoadjuvant Chemotherapy Interval Debulking Surgery Compared with Primary Debulking Surgery on Patients with Advanced Epithelial Ovarian Carcinoma,P38MAPK Signaling Pathway is Involved in Expression Regulation of uPA Protein in Ovarian Cancer Cells and Tissues,Cathepsin L Promotes Invasion and Migration of Human Ovarian Cancer Cell Line SKOV3,Progress in Relevance of Milky Spots and Peritoneal Carcinomatosis,hMSH2 Expression in Ovarian Epithelial Cancer Tissues and Its Relationship with Chemoresistance,Treatment Advances of Peritoneal Metastasis from Gastric Cancer,Biological Characteristics of Paclitaxel-resistance Ovarian Cancer Cell Lines and Cryopreservation Methods
Full-Text Cite this paper Add to My Lib
摘要 目的 研究细胞减灭术（CRS）加腹腔热灌注化疗（HIPEC）治疗卵巢癌腹膜转移癌的疗效及安全性。方法 46例晚期（A组，FIGO Ⅲc/Ⅳ期，n=16和复发性，B组，n=30）卵巢癌腹膜癌患者接受了CRS+HIPEC治疗，分析其临床资料，主要终点指标为总生存期，次要指标为安全性。结果 A、B两组患者的中位总生存期（OS）分别为74.0月和57.5月（P=0.68）。腹膜癌指数（PCI）≤20（n=24）和＞20（n=22）的中位OS分别为76.6和38.5月（P=0.01）。CC 0~1分和CC 2~3分的中位OS分别为79.5和24.3月（P=0.00）。对复发性卵巢癌腹膜癌患者来说，铂类敏感型和耐药型患者的中位OS分别为6 5 . 3 和2 0 . 0 月（P=0.05）。无围手术期死亡病例，5例患者出现术后并发症。多因素分析显示，CC 0~1分、术后化疗≥6周期为改善生存的独立预后因素。结论 CRS+HIPEC可延长卵巢癌腹膜癌患者的总生存期，安全可行
Full-Text
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133
